#Tokyo school life igg series#

R11 cell line cultured under neural stem cell culture conditions: II: Combination valproate + bortezomib induces apoptosis in vitro (Asklund et al. Expression of cancer stem cell markers was evaluated вЂ¦ A numeral followed by the letter U, e. We hope to lead this project to success as an example of Japanese style's new innovation cycle.Gsc nu viability Get to know us. Industry gives them a concrete shape for the products. Industry, academia and government should cooperate вЂ“ academia creates new pharmaceutical candidates generated by new technologies and concepts government supports to cultivate them The current market of antibody drugs is dominated by foreign companies, although only a few of antibody drugs are made by Japanese companies. The teams work collaboratively to establish the technical foundation for the development of a variety of new advanced antibody drug.

They will also develop new antibodies directed to areas that have not been targeted by current antibody drugs. The Takahashi Research Team of Kyowa Hakko Kirin Co., Ltd will evaluate the efficacy of the developed antibodies from the point of view as a development company of antibody drugs. The Kanayama Research Team of RIKEN who has newly joined to the project focuses on the research of in vivo imaging using antibody radionuclide conjugate produced in this project. They will establish a new chemical modification system to improve the functions of antibodies such as ADC. The Hayashi Research team in Tokyo University of Pharmacy and Life Sciences is skilled in peptide mimetics and development of anticancer drugs based on peptide chemistry. The Ito Research Team has enough experience and knowledge's in designing specific peptide and antibody to target molecules by phage display library.Д«y this technique, they will develop molecules (peptide and antibody) that have new effector functions to target inner cell and brain.

The project is jointly conducted by the Ito Research Team of Kagoshima University (project leader: Professor Yuji Ito), Tokyo University of Pharmacy and Life Sciences (project coleader: Professor Yoshio Hayashi), RIKEN center for Molecular Imaging Science (project coleader: Researcher Yosuke Kanayama) and the research team of Kyowa Hakko Kirin Co., Ltd (project coleader: Senior Researcher Nobuaki Takahashi). It also includes the development of antibody drugs against disease-associated target molecules in brain and inner cell which have not been targeted by antibody drugs currently.

#Tokyo school life igg series#

This project uses a unique technology of a new peptide reagent that can specifically modify human IgG quickly and efficiently,ДЄnd aims to create a series of antibody drugs with a wide array of advanced functions by connecting the specific molecules with the effector function to antibody. We believe that in order to achieve further progress of biotherapeutics, we need to improve and diversify the effector functions of antibody, as well as to further explore new target molecules for antibody therapy to treat the diseases.

However, the target antigen for many of antibody drugs is limited to the extracellular soluble factors and/or membrane-bound cell surface receptor,ДЄnd their action is mainly based on the effector functions such as binding inhibition to the receptor of ligand, ADCC (Antibody-dependent cellular cytotoxicity), and CDC (Complement-dependent cellular cytotoxicity).ДЄlthough new developments have been made in recent years, they are antibody fragment drugs, such as Fab, Nanobodies (VHH) and BiTE (Bispecific T Cell-Engaging Antibody), or ADC (Antibody-Drug Conjugate). Almost fifty antibody drugs have been developed to treat various diseases.